118 related articles for article (PubMed ID: 21782242)
1. The role of regulatory T cells during the attenuation of graft-versus-leukemia activity following donor leukocyte infusion in mice.
Choi MS; Lim JY; Cho BS; Kim YJ; Chung NG; Jeong DC; Youn H; Lee C; Choi EY; Min CK
Leuk Res; 2011 Dec; 35(12):1549-56. PubMed ID: 21782242
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
3. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect.
Sprangers B; Van Wijmeersch B; Fevery S; Waer M; Billiau AD
Nat Clin Pract Oncol; 2007 Jul; 4(7):404-14. PubMed ID: 17597705
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
[TBL] [Abstract][Full Text] [Related]
5. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
6. Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism.
Mapara MY; Kim YM; Marx J; Sykes M
Transplantation; 2003 Jul; 76(2):297-305. PubMed ID: 12883182
[TBL] [Abstract][Full Text] [Related]
7. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
8. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.
Duramad O; Laysang A; Li J; Ishii Y; Namikawa R
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405
[TBL] [Abstract][Full Text] [Related]
10. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of murine leukemia following non-myeloablative conditioning with naïve or G-CSF mobilized blood or bone marrow stem cells.
Weiss L; Or R; Slavin S; Naparstek E; Reich S; Abdul-Hai A
Cancer Immunol Immunother; 2004 Apr; 53(4):358-62. PubMed ID: 14605765
[TBL] [Abstract][Full Text] [Related]
12. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity.
Durakovic N; Radojcic V; Powell J; Luznik L
Transplantation; 2007 Mar; 83(5):631-40. PubMed ID: 17353785
[TBL] [Abstract][Full Text] [Related]
14. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
Du B; Li DP; Xu KL; Pan XY
Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical effects of IFN-gamma in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury.
Wang H; Asavaroengchai W; Yeap BY; Wang MG; Wang S; Sykes M; Yang YG
Blood; 2009 Apr; 113(15):3612-9. PubMed ID: 19211507
[TBL] [Abstract][Full Text] [Related]
17. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
[TBL] [Abstract][Full Text] [Related]
18. The influence of pretransplantation conditioning on graft-vs.-leukemia effect in mice.
Lim JY; Choi MS; Youn H; Choi EY; Min CK
Exp Hematol; 2011 Oct; 39(10):1018-29. PubMed ID: 21767512
[TBL] [Abstract][Full Text] [Related]
19. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
[TBL] [Abstract][Full Text] [Related]
20. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
